China has approved the world's first vaccine against XBB descendent lineages of SARS-CoV-2 for emergency use. The Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 Trivalent (XBB.1.5+BA.5+Delta) Protein Vaccine, developed by WestVac Biopharma/West China Medical Center, Sichuan University, is a broad-spectrum COVID-19 vaccine against multiple prevalent subvariants locally and internationally, including Omicron subvariants XBB.1.5, XBB1.16, XBB1.9.1, XBB.2.3, BA.5, BF.7, BQ.1 and BA2 75 with an excellent safety profile and a protective efficacy of 93%. The WHO Technical Advisory Group on COVID-19 Vaccine Composition advised that new formulations of COVID-19 vaccines should aim to induce antibody responses that neutralize XBB descendent lineages as the rate of "second infection" is rising due to stronger transmission and immune escape capability.
Keywords: China, vaccine approval, XBB descendent lineages, COVID-19 vaccine, WestVac Biopharma
WestVac Biopharma has successfully developed a vaccine covering